Predictors of circulating INTERLEUKIN-6 levels in head and neck cancer patients

Cottin, Sylvine Carrondo; Turcotte, Stéphane; Douville, Pierre; Meyer, François; Bairati, Isabelle

doi:10.1186/s41199-018-0029-5

Cited by 13 publications

(18 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of HPV in the pathogenesis of a subset of head and neck tumours, in particular in oropharyngeal squamous cell tumours (OPSCCs), has been well established [ 30 , 31 ]. Patients with HPV-related cancers are more frequently younger and with a better prognosis than those with OPSCCs HPV-negative [ 31 ]. Numerous studies in the literature show an increased risk of SPCs onset after anogenital HPV-related lesion [ 6 – 8 , 10 , 23 , 26 ].…”

Section: Discussionmentioning

confidence: 99%

“…Also sexual behaviours as unprotected oral sex and number of lifetime partners are considered risk factors. With the exception of HPV16, the HPV types that infect the cervix are different from those of oral area, and carcinogenesis mechanisms are not identical, even not yet fully understood [ 31 ]. OPSCC arise in a different epithelium from the cervical one without transformation zone, and no preinvasive oral lesion can be identified up to date.…”

Section: Discussionmentioning

confidence: 99%

“…OPSCC arise in a different epithelium from the cervical one without transformation zone, and no preinvasive oral lesion can be identified up to date. HPV genome integration occurs with different patterns: in cervical cancer through the classic E2 breakpoint, while in OPSCC throughout the entire genome, more frequently in E1 [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Risk of HPV-related extra-cervical cancers in women treated for cervical intraepithelial neoplasia

et al. 2020

View full text Add to dashboard Cite

Background The aim was to estimate the risk of subsequent extra-cervical Human Papillomavirus (HPV) related cancer in patients surgically treated for high grade cervical intraepithelial neoplasia (CIN 2–3). This is the first study in Italy investigating the occurrence of extra-cervical tumors in this cohort of patients. Methods 3184 patients surgically treated for CIN2–3 since 1992 at the Department of Surgical Sciences of University of Torino were considered. The risk of HPV-related cancer was calculated as Standardized Incidence Ratio (SIR), using as expected values tumour age specific incidence of resident population. Results 173 second primary cancer (SCPs) were identified. SIR to develop cancer after treatment for CIN2–3 was 2.2 (CI 95% 1.89–2.50). Among these occurrences, 10 are in HPV related sites: 1 anus (SIR = 1.8; 0.04–10.0), 3 vagina (SIR = 12.4; 2.56–36.3), 1 vulva (SIR = 1.7; 0.04–9.59), 5 oropharynx (SIR = 8.5; 2.76–19.8). Significant risk has been also recorded for pulmonary (SIR = 3.1; 0.70–5.27) and bladder (SIR = 4.05; 1.10–10.56), with smoking as possible cofactor. We also found increased risk for breast (SIR = 2.4; 2.07–2.84) and ovarian cancers (SIR = 2.1; 1.13–3.49), probably due to an higher adherence to spontaneous and programmed screening programs. Conclusions Our study supports the hypothesis of an increased risk of HPV-related tumours for CIN treated patients, mostly for CIN3. It is conceivable the need of early diagnosis for these cancers in this higher-risk populations.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Risk of HPV-related extra-cervical cancers in women treated for cervical intraepithelial neoplasia

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The incidence of HPV-positive OPC patients is rapidly increasing [ 24 ] and treatment deintensification, in an effort to reduce toxicity while preserving high survival rates, is currently being explored in this group [ 25 ]. Establishing a robust NTCP model for RIHT could possibly allow treatment plan optimization [ 26 ] or selection of patients for emerging treatment techniques, such as proton therapy [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

Radiation-Induced Hypothyroidism in Patients with Oropharyngeal Cancer Treated with IMRT: Independent and External Validation of Five Normal Tissue Complication Probability Models

Nowicka

Tomasik

Papis-Ubych

et al. 2020

Cancers

View full text Add to dashboard Cite

We aimed to externally validate five normal tissue complication probability (NTCP) models for radiation-induced hypothyroidism (RIHT) in a prospectively recruited cohort of 108 patients with oropharyngeal cancer (OPC). NTCP scores were calculated using original published formulas. Plasma thyrotropin (TSH) level was additionally assessed in the short-term after RT. After a median of 28 months of follow-up, thirty one (28.7%) patients developed RIHT. Thyroid mean dose and thyroid volume were significant predictors of RIHT: odds ratio equal to 1.11 (95% CI 1.03–1.19) for mean thyroid dose and 0.87 (95%CI 0.81–0.93) for thyroid volume in univariate analyses. Two of the evaluated NTCP models, published by Rønjom et al. and by Boomsma et al., had satisfactory performance with accuracies of 0.87 (95%CI 0.79–0.93) and 0.84 (95%CI: 0.76–0.91), respectively. Three remaining models, by Cella et al., Bakhshandeh et al. and Vogelius et al., performed significantly worse, overestimating the risk of RIHT in this patient cohort. A short-term TSH level change relative to baseline was not indicative of RIHT development in the follow-up (OR 0.96, 95%CI: 0.65–1.42, p = 0.825). In conclusion, the models by Rønjom et al. and by Boomsma et al. demonstrated external validity and feasibility for long-term prediction of RIHT in survivors of OPC treated with Intensity-Modulated Radiation Therapy (IMRT).

show abstract

“…Besides a role in the immune reaction, IL-6 is reported to have metabolic functions (7). Pro-inflammatory cytokine secretion in the blood is associated with an immune response that can be seen in some patients with head and neck cancer before treatment is initiated (8). Patients with the highest levels of pro-inflammatory cytokines were reported to have the poorest prognosis.…”

Section: Introductionmentioning

confidence: 99%

Systemic Inflammatory Reaction in Patients With Head and Neck Cancer—An Explorative Study

et al. 2019

View full text Add to dashboard Cite

Aim: To assess the longitudinal pattern of pro-inflammatory cytokines and growth factors in serum up to 1 year following treatment for head and neck cancer.Materials and Methods: Patients with newly diagnosed, curable head and neck cancer were included (n = 30). The most common subsite was oropharynx (n = 13) followed by oral cavity (n = 9). Blood was drawn from all patients at regular intervals (before treatment, 7 weeks after the start of the treatment, and at 3 months and 1 year after termination of treatment) and analyzed for cytokines (Il-1β, Il-2, Il-4, Il-5, Il-6, Il-8, Il-10, GM-CSF, TNF-α, and IFN-γ) and growth factors (G-CSF, FGF-2, EGF, and VEGF).Results: The time point of the peak level of pro-inflammatory cytokines was 7 weeks after start of treatment which corresponded for the majority of patients with termination of radiotherapy or chemoradiotherapy. Patients undergoing chemoradiotherapy exhibited a significant increase of IL-1β, IL-6, and IL-10 at 7 weeks as compared to pre-treatment levels. At 1 year after termination of treatment four patients experienced recurrence of disease while 26 patients were considered disease-free. The patients with recurrence had significantly higher levels of IL-1β, IL-6, IL-8, and IL-10 at 7 weeks after the start of treatment than patients without recurrence. Correlated with T stadium patients with T3-T4 had higher levels of IL-1β and IL-8 than patients with T1-T2 7 weeks after the start of treatment.Conclusions: The observed immune response in this explorative study demonstrates that chemoradiotherapy may induce not only a local treatment effect on the immune system but also effects far outside the irradiated field. The result of the study indicates that analysis of a pro-inflammatory panel of cytokines in serum at 7 weeks after the start of treatment could be of prognostic value in patients with head and neck cancer. Further study of a larger cohort could help identify patients at larger risk for recurrent disease with measurements of pro-inflammatory cytokines under and after treatment.

show abstract

Predictors of circulating INTERLEUKIN-6 levels in head and neck cancer patients

Cited by 13 publications

References 63 publications

Risk of HPV-related extra-cervical cancers in women treated for cervical intraepithelial neoplasia

Risk of HPV-related extra-cervical cancers in women treated for cervical intraepithelial neoplasia

Radiation-Induced Hypothyroidism in Patients with Oropharyngeal Cancer Treated with IMRT: Independent and External Validation of Five Normal Tissue Complication Probability Models

Systemic Inflammatory Reaction in Patients With Head and Neck Cancer—An Explorative Study

Contact Info

Product

Resources

About